Illkirch-Graffenstaden, France
Illkirch-Graffenstaden, France

Time filter

Source Type

NEW YORK & STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: Bristol-Myers Squibb Company (NYSE: BMY) and Transgene (Paris:TNG) today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors ha


SAN FRANCISCO & STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: SillaJen, Inc., (KOSDAQ : 215600), société de biotechnologie spécialisée dans le développement d’immunothérapie oncolytique contre le cancer, et Transgene (Paris:TNG) (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des produits d’immunothérapie basés sur des vecteurs viraux contre les cancers et les maladies infectieuses, annoncent l’inclusion du premier patient européen dans l’étude randomisée et o


NEW YORK & STRASBOURG, France--(BUSINESS WIRE)--Regulatory News : Bristol-Myers Squibb Company (NYSE: BMY) et Transgene (Paris:TNG) annoncent la signature d’un accord de collaboration pour la conduite d’une étude clinique visant à évaluer la tolérance et l’efficacité du candidat vaccin thérapeutique TG4010 associé à Opdivo (nivolumab) de Bristol-Myers Squibb et à une chimiothérapie standard (CT) en 1ère ligne de traitement du cancer du poumon non à petites cellules (non-small cell lung cancer -


NEW YORK & STRASBOURG, France--(BUSINESS WIRE)--$BMY--Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer


SEOUL, South Korea & SAN FRANCISCO & STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Transgene (Paris:TNG) (Euronext: TNG), a French biotechnology company focused on discovering and developing immune-targeted immunotherapies for the treatment of cancer and infectious diseases, have enrolled the first European patient in the ongoing multi


Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022. Factors stimulating the market growth are increasing demand for food, growing area of biotech crops, rising demand for biofuels & bio plastic production and demand for animal feed. Furthermore, increased investments and capital inflow for industry participants and research & development within Africa and Asia Pacific region will provide more growth prospects towards the market. However, stringent government rules and unacceptability of genetically modified crops will hinder market growth. Transgenic seeds and synthetic biology-enabled products will be the largest segment of the agricultural biotechnology application market. Soybean is anticipated to dominate the transgenic crops segment. North America commanded the regional market owing to increasing genetically modified crop cultivation. Asia Pacific is the fastest growing market due to large scale consumption for food, fiber, feed, and energy production. Some of the key players in global Agricultural Biotechnology market are ABBA GAIA S.L., Affymetrix Inc., Arcadia Biosciences Inc., Quinvita Nv, Bayer Cropscience Ag, Biocentury Transgene Co. Ltd., Rosetta Green, Eurofins Genescan Ag, Cofactor Genomics, Cellectis Plant Sciences, Edenspace Systems Corporation, Douglas Scientific, Dow Chemical Company, Dr. Chip Biotech Inc., Evogene Ltd., Insectigen Inc., Mendel Biotechnology Inc., Metabolix Inc., Plant Biosciences Ltd., Synthetic Genomics Inc., Targeted Growth Inc. and Vilmorin & Cie Sa. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/959894-agricultural-biotechnology-global-market-outlook-2016-2022


News Article | November 9, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma)  and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Basal Cell Carcinoma (Basal Cell Epithelioma)  - Pipeline Review,H2 2016 addition with 27 market data tables and 12 figures, spread across 112 pages is available at http://www.rnrmarketresearch.com/basal-cell-carcinoma-basal-cell-epithelioma-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Biofrontera AG,Biosceptre (Aust) Pty Ltd,Cannabis Science, Inc,Genextra S.p.a.,Ignyta, Inc. Laboratories Ojer Pharma S.L.,MediGene AG,Merck & Co., Inc.,PellePharm, Inc.,Provectus Biopharmaceuticals, Inc.,Redx Pharma Plc,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.,Transgene SA Inquire before buying  http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748017(This is a premium report price at US$2000 for a single user PDF license).


News Article | November 9, 2016
Site: www.newsmaker.com.au

The Global market for Therapeutic vaccines is expected to reach US $4.82 billion by the end of 2020 growing at a CAGR of around 33.6% from 2015 to 2020. Several new approaches are being developed in order to boost the immune response to the cancerous cells.These technical advancements are expected to add powerful new components to the standard cancer treatments.In the pipeline, therapeutic vaccines are also in development to treat infectious diseases such as the Human Immunodeficiency Virus (HIV), neurological disorders such as Alzheimers disease, autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, and other conditions such as hypertension. The Global Therapeutic Vaccines Market is segregated on the basis of Autoimmune Disease Vaccines (Type I Diabetes), Neurological Disease Vaccines (CAD106, ACC-001, Alzheimer's Disease, Parkinsons Disease Vaccine and Other Disease Vaccines), Cancer Vaccines (TroVax, PR1 Peptide Vaccine, Multikine, CYT004-MelQbG10 etc..), and Infectious Disease Vaccines (HIV/AIDS, Hepatitis C, and Other Infectious Disease Vaccines) & Region (North America, Europe, Asia Pacific & Rest of the World). The Favorable government funding for vaccine development, increasing investments by the companies Technological advancements, rising prevalence of disease are the major factors that are driving the market growth. Huge capital expenditures and Stringent Regulatory policies are hindering the market growth. What the report offers:  • Market Definition for the specified topic along with identification of key drivers and restraints for the market.  • Market analysis for the Global Therapeutic vaccines Market in Healthcare Industry, with region specific assessments and competition analysis on a global and regional scale.  • Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.  • Identification and analysis of the Macro and Micro factors that affect the Global Therapeutic vaccines Market in Healthcare Industry on both global and regional scale.  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information. Introduction  Study Deliverables  Market Definition  Sizing Units  Base Currency  Review and Forecast Period Years  General Study Assumptions  Research Methodology  Introduction  Analysis Methodology  Econometric Forecast Model  Research Assumptions  Executive Summary  Key Inferences  Market Characterisation  Current Market Scenario  Market Overview  New Developments  Porter’s Five Forces  Bargaining Power of Suppliers  Bargaining Power of Consumers  Threat of New Entrants  Threat of Substitute Products and Services  Competitive Rivalry within the Industry  Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis  Drivers  Restraints  Opportunities  Challenges  Therapeutic Vaccines Market Segmentation  By Types  Autoimmune Disease Vaccines  Neurological Disease Vaccines  Cancer Vaccines  Infectious Disease Vaccines  By Geography  Asia Pacific  Europe  North America  Middle East and North Africa  Latin America  Competitive Landscape  Merger and Acquisition Analysis  New Product Launches  Agreements, Collaborations & Partnerships  Company Profiling  Antigenics  Bavarian Nordic  Celtic Pharma  Curevac  Cytos Biotechnology  GlaxoSmithKline  Pfizer  Merck Kgaa (Merck Serono)  Novartis  Transgene  Vaccinogen  Analyst Outlook for Investment Opportunities  Future Outlook of the Market


News Article | December 15, 2016
Site: globenewswire.com

Lyon, 15 December 2016, ELSALYS BIOTECH announces the acquisition of development and marketing rights for TG3003 anti-CD115 (as of now ELB041) from TRANSGENE, a monoclonal antibody that inhibits a highly immunosuppressive macrophage subpopulation: type-2 macrophages. In exchange for the license granted to ELSALYS BIOTECH (along with all related sublicensing rights), TRANSGENE will be eligible to receive milestone payments until the medicinal product is registered and will receive royalties based on future sales. M-CSF is a cytokine essential to the survival and differentiation of myeloid lineage cells (monocytes, macrophages, dendritic cells.). The M-CSF receptor (M-CSF-R or CD115) therefore proves to be a promising therapeutic target to modulate the activity of some of these cells, notably those implicated in the tumoral progression as the Tumor Associated Macrophages (TAM). These TAM are in effect made up of 2 subpopulations: the so-called type M1 « tumor killers » macrophages and the type M2 macrophages that suppress the immune response and promote the growth and dissemination of cancer cells.  Thus, in most cancers, the strong presence of these M2 macrophages in the center of the tumor is seen as a factor of poor prognosis The first studies conducted by TRANSGENE with the anti-CD115 ELB041 demonstrate the latter could counter this deleterious effect: it lifts the immunosuppression mediated by the M2 macrophages (Immune Checkpoint Inhibitor or ICI) while restoring the ability of the immune system to destroy the tumor cells (Antibody-Dependent Cell-mediated Cytotoxicity or ADCC). In the light of these encouraging data, ELSALYS BIOTECH will now initiate a preclinical study targeting proof-of-concept in immuno-oncology "ELB041 possesses unique properties. Beyond its dual mechanism of action, it selectively inhibits the formation of M2 macrophages and, unlike the anti-CD115s under development, does not block the interaction between M-CSF and its receptor, CD115, but modulates its activity. Therefore, it should not induce an increase, potentially toxic, in the concentration of serum M-CSF thereby maintaining the viability of myeloid cells. Alone or in combination, it has a favorable efficacy/toxicity ratio." Dr. Jacques MIZRAHI, Scientific Director at ELSALYS BIOTECH, pointed out. "Our goal now is to undertake a clinical assessment of anti-CD115 before the end of 2018." "This new antibody provides a wonderful opportunity for ELSALYS BIOTECH. It highlights the trust we have received from TRANSGENE, which is one of the company's founding shareholders, but also a leader in immunotherapy which intends to focus on therapeutic vaccines and oncolytic viruses" said Dr. Christine GUILLEN, CEO and Co-founder of ELSALYS BIOTECH. "This licensing agreement consolidates our position in immunotherapy antibodies targeting tumors and their immune and/or vascular microenvironment. We now have five development programs in this field, giving ELSALYS BIOTECH an optimum risk profile." ELB041 is a humanized antibody, potentially "best-in-disease", that targets CD115, the M-CSF (Macrophage Colony-Stimulating Factor) found on the surface of macrophages and, more generally, on all cells in the so-called myeloid lineage. An active member of the organism's first line of defense, macrophages are cells with a dual personality: nested in the heart of tumors, some of them promote the immune reaction and contribute to tumor destruction (M1 macrophages), whereas others (M2 macrophages) promote the growth and dissemination of cancer cells and slow the action of the lymphocytes that eliminate them. Many clinical studies have demonstrated that patients dealing with tumors that are highly infiltrated by M2 macrophages run a high risk of relapse. More recently, scientists have discovered that macrophages' functions actually evolve in response to changes in the tumor microenvironment. These studies led TRANSGENE to develop an antibody that is able to inhibit the activity of these deleterious macrophages. In a first series of in vitro and in vivo studies TRANSGENE has already shown that anti-CD115: ELSALYS BIOTECH is a fast-growing biotechnology company that designs and develops "best-in-disease" therapeutic antibodies that target tumors and their immune and/or vascular microenvironment. By restoring the ability of immune cells to recognize and kill tumors (Immune Checkpoint Inhibitors or ICI) or by blocking the mechanisms that promote their growth (targeted antibodies), ELSALYS BIOTECH widens the range of combinations of oncology and ophthalmology in novel strong potential therapeutic targets. To drive its developments, the company relies on an academic network of international standing, an R&D platform that covers from targets sourcing to clinical development of drug candidates and a team of experts with solid experience in immuno-oncology, antibodies development and partnerships. Today ELSALYS BIOTECH has five R&D proprietary development programs in oncology and in ophthalmology. Founded in 2013, ELSALYS BIOTECH is made up of a team of 14 people and managed by Dr Christine GUILLEN. Its founding shareholders are Transgene and Sofimac Partners, joined by IM Europe and Crédit Agricole Création in 2015. The company is located in the heart of the Biodistrict Lyon Gerland.


STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today presented a poster on TG1050 preclinical results at the AASLD (American Association for the Study of Liver Diseases) Liver Meeting 2016, Boston (MA). TG1050 is a therapeutic vaccine for the treatment of chronic hepatitis B (or HBV1 infection). The abstract published in

Loading Transgene collaborators
Loading Transgene collaborators